Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Vets warned of monensin toxicity in dogs
dog walking
So far, almost all reports involve farm dogs but due to the bolus regurgitation process, dogs walked on farmland are also at risk.
SPC for Kexxtone changed after rise in accidental exposure reports
 
Veterinary surgeons are being warned of the risks of monensin exposure to non-target species.

In 2015, the Veterinary Medicines Directorate (VMD) saw an increase in reports of accidental canine exposure to Kexxtone 32.4g (monensin), the drug used in cattle feed to control ketosis.

Reported symptoms included neurological issues, such as seizures, lethargy, muscular problems, locked jaws, problems with balance, confusion, vomiting and death.

So far, almost all reports involve farm dogs but due to the bolus regurgitation process, dogs walked on farmland are also at risk.

As a result, the VMD requested that the following warning be added to the Summary of Product Characteristics (SPC):

'Do not allow dogs, horses, other equines or guinea fowl access to formulations containing monensin. Due to the risk of bolus regurgitation, do not allow these species access to areas where treated cattle have been kept. Ingestion or oral exposure to monensin can be fatal in these species.'

Writing in Veterinary Record letters, the VMD suggested that when prescribing Kexxtone, vets should advise clients of the dangers to non-target species, whilst also remaining aware of the effects of monensin when dealing with cases that present neurological or myopathic problems.

Vets are encouraged to report all adverse reactions to the applicable marketing authorisation holder, or to the VMD via: www.gov.uk/report-veterinary-medicine-problem

Become a member or log in to add this story to your CPD history

Submissions open for BSAVA Clinical Research Abstracts 2026

News Story 1
 The BSAVA has opened submissions for the BSAVA Clinical Research Abstracts 2026.

It is an opportunity for applicants to present new research on any veterinary subject, such as the preliminary results of a study, discussion of a new technique or a description of an interesting case.

They must be based on high-quality clinical research conducted in industry, practice or academia, and summarised in 250 words.

Applications are welcome from vets, vet nurses, practice managers, and students.

Submissions are open until 6 March 2026. 

Click here for more...
News Shorts
Survey seeks ruminant sector views on antimicrobial stewardship

A new survey is seeking views of people working in the UK ruminant sector on how to tackle the challenge of demonstrating responsible antibiotic stewardship.

Forming part of a wider, collaborative initiative, the results will help identify the types of data available so that challenges with data collection can be better understood and addressed.

Anyone working in the UK farming sector, including vets and farmers,is encouraged to complete the survey, which is available at app.onlinesurveys.jisc.ac.uk